Salarius Pharmaceuticals is an emerging biotechnology company developing targeted therapies to treat pediatric and other cancers, including advanced solid tumors. The lead compound Seclidemstat represents a potential paradigm shift in the treatment of cancer and we are initially targeting Ewing sarcoma, a devastating pediatric, adolescent and young adult bone cancer where no targeted therapies are currently available.
Mr. Arthur is a senior life sciences executive with more than 35 years of US and global pharmaceutical experience. During his career, he has built, launched and managed pharmaceutical brands, including drug delivery systems, by integrating strategy, pricing, development, clinical planning, manufacturing, branding and promotional requirements into lifecycle plans, demand realization strategies/tactics and affiliate launches. His extensive experience includes the US, EU, Asia and emerging markets.
Mr. Arthur earned a BS in Chemical Engineering from North Carolina State University, a Master of Business Administration from the Duke University Fuqua School of Business, and he is a licensed Professional Engineer and Six Sigma Green Belt.